P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE
| Autor: | Susanne Ostrowitzki, Reina N. Fuji, Paulo Fontoura, Angelica Quartino, Michael Rabbia, Andres Schneider, Howard Mackey, Jillian Smith, Kaycee M. Sink, Francis Warren, Susan Yule, Rachelle S. Doody |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Epidemiology business.industry Health Policy Disease Psychiatry and Mental health Cellular and Molecular Neuroscience Developmental Neuroscience Baseline characteristics Internal medicine Phase (matter) Crenezumab medicine Cardiology Neurology (clinical) Geriatrics and Gerontology business |
| Zdroj: | Alzheimer's & Dementia. 15 |
| ISSN: | 1552-5279 1552-5260 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|